1. A combination comprising: (i) a compound of structure (I): or a pharmaceutically acceptable hydrate and / or salt thereof, and (ii) a compound of structure (II): or a pharmaceutically acceptable salt thereof. The combination of claim 1, wherein the compound of structure (I) is in the form of a ditosylate salt monohydrate. A combination kit containing the combination of claim 1 or 2, together with a pharmaceutically acceptable carrier or carriers. 4. The combination of claim 1, wherein the amount of the compound of structure (I) is an amount selected from the interval from 750 mg to 1250 mg, and this amount is administered once a day in the form of one or more tablets, and the amount of the compound of structure (II) represents an amount selected from the range of 50 mg to 300 mg, and this amount is administered once a day. The combination of claim 1 for use in the treatment of cancer. 6. The combination according to claim 5 for use in the treatment of cancer in a person in need thereof, which comprises administering in vivo a therapeutically effective amount of a combination, where the combination is administered for a certain period, and where the combination is administered for a period of time. The combination of claim 6, wherein the amount of N- {3-chloro-4 - [(3-fluorobenzyl) oxy] phenyl} -6- [5 - ({[2- (methanesulfonyl) ethyl] amino} methyl) -2 -furyl] -4-quinazolinamine, or a pharmaceutically acceptable hydrate and / or salt thereof, are selected from about 750 mg to about 1250 mg, and this amount is administered once a day in the form of one or more tablets, and the amount of N is {(1S ) -2-amino-1 - [(3,4-difluorophenyl) methyl] ethyl} -5-chloro-4- (4-chloro-1-methyl-1H-pyrazol-5-yl) -2-furancarboxamide, or from a pharmaceutically acceptable salt thereof, from about 50 mg to about 300 mg are selected, and this amount is administered once a day n.8. The combination of claim 7, wherein the amount1. Комбинация, включающая в себя:(i) соединение структуры (I)
